The Medical Letter on Drugs and Therapeutics
Talimogene Laherparepvec (Imlygic) for Unresectable Melanoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved talimogene laherparepvec (Imlygic – Amgen), a genetically modified herpes simplex virus, for intralesional treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma that has recurred following surgery. It is the first oncolytic virotherapy to become available in the US.

MECHANISM OF ACTION — Melanoma tumors are immunogenic and often accessible, which makes them good targets for intralesional viral immunotherapy.1,2 Talimogene laherparepvec (T-VEC) is a herpes simplex type 1 virus (HSV-1) that has been modified to reduce its pathogenicity in healthy cells and promote its replication in tumor cells. The virus is also encoded with the gene for granulocyte macrophage-colony stimulating factor (GM-CSF), which induces T-cell proliferation and activation.3 Virus-induced tumor ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Talimogene Laherparepvec (Imlygic) for Unresectable Melanoma
Article code: 1486c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian